Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: An ancillary study derived from a randomized clinical trial

Loïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, Isabelle Ray-Coquard, Axel Le Cesne, Emmanuelle Bompas, Jean Yves Blay, Antoine Italiano, Olivier Mir, Thomas Ryckewaert, Yves Toiron, Luc Camoin, Anthony Goncalves, Nicolas Penel, Marie Cécile Le Deley

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    15 Citations (Scopus)

    Résumé

    Background: We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel. Methods: Circulating pro/anti-angiogenic factors were assessed on day 1 (D1) and day 8 (D8). The prognostic value for progression-free survival (PFS) was evaluated using a Cox model with biomarkers as continuous variables. Results: Among the 51 patients enrolled and treated in this trial, biomarker analysis was performed for 42: 18 in Arm A (single-agent) and 24 in Arm B (combination). With a median follow-up of 46 months, PFS was 5.5 versus 5.7 months, respectively (p = 0.75). According to univariate analysis, factors associated with a poor PFS were as follows: visceral angiosarcoma, de novo angiosarcoma, and high PlGF and low VEGF-C baseline values. In multivariate analysis, de novo angiosarcoma (HR = 2.5; p = 0.024) and baseline VEGF-C value (HR = 0.7; p = 0.003) were significant prognostic factors. We observed a significant increase in circulating PlGF (< 0.001) and a decrease in VEGF (< 0.001) during bevacizumab treatment. An increase in FGF was associated with a poor outcome. Conclusions: De novo angiosarcoma and a low baseline level of VEGF-C were found to be associated with a poor prognosis. Addition of bevacizumab induces major changes in circulating biomarkers (VEGF and PlGF) in a short timeframe without impacting PFS. Trial registration: Retrospectively registered on EudraCT N° 2009-017020-59 and NCT01303497 (February 24, 2011).

    langue originaleAnglais
    Numéro d'article963
    journalBMC Cancer
    Volume18
    Numéro de publication1
    Les DOIs
    étatPublié - 11 oct. 2018

    Contient cette citation